Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

HomeOncotype DX® GPS (Prostate)
Pin your most used calculators here by clicking the star in the dropdown.

Oncotype DX® GPS (Prostate)

Clinical Context & Background

The Oncotype DX Genomic Prostate Score (GPS) assay analyzes the expression of 17 genes to predict the biological aggressiveness of prostate cancer. It is validated for use in men with clinically localized prostate cancer (NCCN Very Low, Low, and Intermediate Risk) to help guide treatment decisions, particularly regarding Active Surveillance.
Primary Source EvidenceKlein EA, Cooperberg MR, Magi-Galluzzi C, et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur Urol. 2014;66(3):550-560.
Formula Logic
GPS Score (0-100) based on 17-gene signature.

Reference Data

GPS ScoreRisk ProfileAdverse Pathology Risk
0 - 20Very LowLow risk of adverse pathology
21 - 40Low / IntermediateIntermediate risk
41 - 100HighHigh risk of adverse pathology

Share This Calculator

Share:

Related Tools

D'Amico Risk ClassificationEpstein Criteria (Insignificant Cancer)PI-RADS™ v2.1 (Prostate MRI)

Evidence-based oncology decision support. Verify with clinical guidelines.